Monitoring temozolomide treatment of low-grade glioma with proton magnetic resonance spectroscopy.

Murphy, P S; Viviers, L; Abson, C; Rowland, I J; Brada, M; Leach, M O; Dzik-Jurasz, A S K

Murphy, P S; Viviers, L; Abson, C; Rowland, I J; Brada, M; Leach, M O; Dzik-Jurasz, A S K.

Affiliation

Murphy PS; Cancer Research UK Clinical Magnetic Resonance Research Group, The Institute of Cancer Research and The Royal Marsden NHS Trust, Sutton, Surrey SM2 5PT, UK.

Br J Cancer ; 90(4): 781-6, 2004 Feb 23.

Article in En | MEDLINE | ID: mdl-14970853

Subject(s)

Antineoplastic Agents, Alkylating/therapeutic use; Brain Neoplasms/drug therapy; Brain Neoplasms/metabolism; Dacarbazine/analogs & derivatives; Dacarbazine/therapeutic use; Glioma/drug therapy; Glioma/metabolism; Magnetic Resonance Spectroscopy; Administration, Oral; Adult; Antineoplastic Agents, Alkylating/administration & dosage; Choline/metabolism; Dacarbazine/administration & dosage; Female; Humans; Male; Temozolomide; Treatment Outcome; Water/analysis

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Brain Neoplasms / Magnetic Resonance Spectroscopy / Antineoplastic Agents, Alkylating / Dacarbazine / Glioma Limits: Adult / Female / Humans / Male Language: En Journal: Br J Cancer Year: 2004 Document type: Article

Fulltext

XML

PubMed Links

Search on Google